Off-Label Use of Atypical AntipsychoticsCause for Concern?

被引：0
作者：
Andrew McKean
Erik Monasterio
机构：
[1] The Princess Margaret Hospital,Pharmacy Department
[2] Hillmorton Hospital,Medlicott Academic Unit
来源：
CNS Drugs | 2012年 / 26卷
关键词：
Major Depressive Disorder; Anxiety Disorder; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Licensed indications for medicines were designed to regulate the claims that can be made about a medicine by a pharmaceutical company. Off-label prescribing (i.e. prescribing a drug for an indication outside of that for which it is licensed) is legal and an integral part of medical practice. In psychiatry, off-label prescribing is common and gives clinicians scope to treat patients who are refractory to standard therapy or where there is no licensed medication for an indication. However, efficacy or safety of such off-label use may not be established.
引用
收藏
页码：383 / 390
页数：7
相关论文
共 50 条
  • [21] Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder: A Survey of Italian Psychiatrists
    Salvi, Virginio
    Cerveri, Giancarlo
    Aguglia, Andrea
    Calo, Salvatore
    Corbo, Mariangela
    Martinotti, Giovanni
    Serafini, Gianluca
    Signorelli, Maria Salvina
    Aguglia, Eugenio
    Amore, Mario
    Biggio, Giovanni
    Di Sciascio, Guido
    Mencacci, Claudio
    JOURNAL OF PSYCHIATRIC PRACTICE, 2019, 25 (04) : 318 - 327
  • [22] Off-Label Use of Antipsychotics and Health Related Quality of Life in Community Living Older Adults
    Bakouni, Hamzah
    Vasiliadis, Helen-Maria
    APPLIED RESEARCH IN QUALITY OF LIFE, 2020, 15 (04) : 991 - 1004
  • [23] Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality
    Berge, Jonas
    Abri, Paul
    Andell, Pontus
    Movahed, Pouya
    Ragazan, Dragos C.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 149 : 352 - 358
  • [24] The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
    Yunusa, Ismaeel
    El Helou, Marie Line
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [25] Off-label psychotropic prescribing for young persons in medium security
    Haw, C.
    Stubbs, J.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (10) : 1491 - 1498
  • [26] Off-Label Prescribing to Children in the United States Outpatient Setting
    Bazzano, Alicia T. F.
    Mangione-Smith, Rita
    Schonlau, Matthias
    Suttorp, Marika J.
    Brook, Robert H.
    ACADEMIC PEDIATRICS, 2009, 9 (02) : 81 - 88
  • [27] Worsening stimulant use disorder outcomes coinciding with off-label antipsychotic prescribing: a commonly unrecognised side effect?
    Amarasekera, Ruvini
    Wood, Evan
    BMJ CASE REPORTS, 2023, 16 (10)
  • [28] Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus
    Black, Kevin J.
    Nasrallah, Henry
    Isaacson, Stuart
    Stacy, Mark
    Pahwa, Rajesh
    Adler, Charles H.
    Alva, Gustavo
    Cooney, Jeffrey W.
    Kremens, Daniel
    Menza, Matthew A.
    Meyer, Jonathan M.
    Patkar, Ashwin A.
    Simuni, Tanya
    Morrissette, Debbi A.
    Stahl, Stephen M.
    CNS SPECTRUMS, 2018, 23 (06) : 402 - 413
  • [29] Use of antipsychotics in Denmark 1997-2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses
    Hojlund, M.
    Andersen, J. H.
    Andersen, K.
    Correll, C. U.
    Hallas, J.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2021, 30
  • [30] FDA requests class label change for atypical antipsychotics
    Reactions Weekly, 2003, 970 (1) : 2 - 2
12345